AIMINGMED

AIMINGMED, founded in 2020, is a research and development-oriented medical technology enterprise with organoid technology as its core. Currently, the company's core team comes from top scientific research institutes and clinical centers such as the National University of Singapore, Yale University, the Chinese Academy of Sciences, and West China Hospital. Relying on the core technology of organoids, the company focuses on the entire process of organoid drug sensitivity testing based on clinical pain points, conducting fully automatic and digital product development for high-throughput equipment and consumables. Core products include the organoid automatic processing and analysis instrument OSCAR, the organoid chip Signoid, and the digital organoid Digituor. Through organoid technology, the company will provide a complete set of solutions that integrate medical treatment, patient care, and research for scenarios such as precision medication testing for cancer patients, innovative scientific research for medical researchers, and new drug screening for pharmaceutical companies. Ultimately, AIMINGMED aims to fulfill its corporate mission: "Giving direction to treatments and hope to life."